SAN FRANCISCO, Aug. 25, 2017 /PRNewswire-USNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in PetMed Express, Inc. (NASDAQ: PETS) to the firm's investigation into possible securities law violations in response to alleged improper opioid sales.
If you purchased or otherwise acquired securities of PetMed before August 23, 2017and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing [email protected].
On August 23, 2017, a blog post by Aurelius Value entitled "PetMed: Exploiting America's Opioid Epidemic" raised several critical questions about PetMed. More specifically, Aurelius alleged PetMed has been targeting the sale of opioid medication like tramadol to individuals, not just pet owners for the pets themselves.
This post drove the price of PetMed shares down $3.19, or about 8% on heavy volume, to close at $36.22 on August 23, 2017.
On August 24, 2017, Benzinga reported ads for PetMed's tramadol were removed from Alphabet Inc.'s Google searches.
"We're investigating the merits of Aurelius' allegations and, if true, the damages suffered by PetMed investors," said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding PetMed should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.